New enzymes and protein engineering have advanced biocatalysis processing toward commercial acceptance. Technology and economic roadblocks must be overcome for the process to be widely embraced by pharma.
Mark Muldowney
Advertisement
Mark Muldowney is head of technology at Sterling Pharma Solutions.
Articles by Mark Muldowney
Advertisement
Latest Updated Articles
Seeking Economies of Scale for BiocatalysisOctober 15th 2021
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
CDMOs, OEMs, and Used Equipment Resellers are Joining Forces to Onshore Pharmaceutical Manufacturing
2
Meeting Tomorrow's Market Requirements: Vetter's Perspective on the Future of Fill & Finish
3
Why Drug Shortages Average 5+ Years: PharmTech Explained
4
ADCs, Degraders, Agonists: 4 Deals CMC Teams Should Track
5